pSivida Limited (ASX: PSD), ry pSiMedica ha received notice of...

pSivida Limited (ASX: PSD), ry pSiMedica ha received notice of allowance for an important new US Patent. Th nic device within a living animal or human bioactive silicon; and (ii)A mto b The Patent is drug delivery d. Leading elcs and chip technology companies have already expressed an interest in exan pSpathvae adding electronics and chip companies looking to develop ‘smart’ devices with po Fonegrst Thpa(r Products protected by patents and patent applications owned by pSiMedica include mthim is pleased to announce that its UK subsidia
s
e Patent contains two main claims:
(i) A method of implanting an electrobody, wherein the device includes
ethod of delivering a drug to a living animal or human by placing the drug e delivered on or within a bioactive silicon structure.
particularly important in assisting to underpin the development of ‘smart’ evices making use of the semi-conductor properties of silicon
ectroni
ploring the development of such devices. pSiMedica is pursuing these opportunities d will continue to advance discussions with potential partners during the coming year. ivida Managing Director, Mr Gavin Rezos said,” We are pleased to add another US tent to our already strong IP portfolio. This new patent will draw further attention in e US to the versatility of the BioSiliconTM technology platform and in particular to large
lu
tential applications in controlled drug delivery and diagnostics.” rmal grant of this patent following payment of the grant fee, which will occur in the xt few weeks, is expected in November 2003. This patent follows 4 earlier patent ants in the key jurisdictions of the United Kingdom and United States and further ngthens pSiMedica’s healthcare claims for the BioSiliconTM technology.
re
e pSiMedica Intellectual Property portfolio consists of 17 patent families, 6 granted tents and over 70 patent applications. pSiMedica owns all of the Intellectual Property oyalty free) for the application of BioSiliconTM.
aterials comprising bioactive, resorbable and biocompatible silicon that are of value in e fabrication of new generations of intelligent drug delivery devices, orthopaedic plants and intelligent diagnostic tools.
-ENDS-